Page 133 - 第10期

第41卷第10期 孙 冰，王海昌. 动脉粥样硬化性心血管疾病高危人群胆固醇管理的临床研究进展［J］.
2021年10月 南京医科大学学报（自然科学版），2021，41（10）：1546-1551 ·1551 ·

hypercholesterolemia［J］. Expert Opin Drug Saf，2019，18 anacetrapib in patients with atherosclerotic vascular dis⁃
（5）：403-414 ease［J］. N Engl J Med，2017，377（13）：1217-1227
［40］ BLOM D J，AVERNA M R，MEAGHER E A，et al. Long⁃ ［49］ BALLANTYNE C M，SHAH S，SAPRE A，et al. A multi⁃
term efficacy and safety of the microsomal triglyceride regional，randomized evaluation of the lipid⁃modifying ef⁃
transfer protein inhibitor lomitapide in patients with ho⁃ ficacy and tolerability of anacetrapib added to ongoing
mozygous familial hypercholesterolemia［J］. Circulation， statin therapy in patients with hypercholesterolemia or

2017，136（3）：332-335 low high⁃density lipoprotein cholesterol［J］. Am J Cardiol，
［41］ MÜLLER H H. Effect of mipomersen on LDL⁃cholesterol 2017，120（4）：569-576
in patients with severe LDL ⁃ hypercholesterolaemia and ［50］ TAHERI H，FILION K B，WINDLE S B，et al. Cholester⁃
atherosclerosis treated by lipoprotein apheresis：correc⁃ yl ester transfer protein inhibitors and cardiovascular out⁃
tions of the report on the randomized MICA ⁃ study［J］. comes：a systematic review and meta⁃analysis of random⁃
Atherosclerosis，2018，27（5）：457-458 ized controlled trials［J］. Cardiology，2020，145（4）：236-
［42］ DUELL P B，SANTOS R D，KIRWAN B A，et al. Long⁃ 250
term mipomersen treatment is associated with a reduction ［51］ BURGESS S，FERENCE B A，STALEY J R，et al. Europe⁃
in cardiovascular events in patients with familial hyper⁃ an prospective investigation into cancer and nutrition⁃car⁃
cholesterolemia［J］. J Clin Lipidol，2016，10（4）：1011- diovascular disease（EPIC⁃CVD）consortium. Association
1021 of LPA variants with risk of coronary disease and the im⁃
［43］ FOGACCI F，FERRI N，TOTH P P，et al. Efficacy and plications for lipoprotein（a）⁃lowering therapies：a mende⁃
safety of mipomersen：a systematic review and meta⁃analy⁃ lian randomization analysis［J］. JAMA Cardiol，2018，3
sis of randomized clinical trials［J］. Drugs，2019，79（7）： （7）：619-627
751-766 ［52］ LAMINA C，KRONENBERG F. Estimation of the required
［44］ LANDMESSER U，HAGHIKIA A，LEITER L A，et al. Ef⁃ lipoprotein（a）⁃lowering therapeutic effect size for reduc⁃
fect of inclisiran，the small⁃interfering RNA against pro⁃ tion in coronary heart disease outcomes：a mendelian ran⁃
protein convertase subtilisin/kexin type 9，on platelets， domization analysis［J］. JAMA Cardiol，2019，4（6）：575-
immune cells，and immunological biomarkers：a pre⁃speci⁃ 579
fied analysis from ORION⁃1［J］. Cardiovasc Res，2021， ［53］ MADSEN C M，KAMSTRUP P R，LANGSTED A，et al.
117（1）：284-291 Lipoprotein（a）⁃lowering by 50 mg/dL（105 nmol/L）may
［45］ RAY K K，STOEKENBROEK R M，KALLEND D，et al. be needed to reduce cardiovascular disease 20% in sec⁃
Effect of 1 or 2 doses of inclisiran on low⁃density lipopro⁃ ondary prevention：a population⁃based study［J］. Arterio⁃
tein cholesterol levels：one⁃year follow⁃up of the ORION⁃ scler Thromb Vasc Biol，2020，40（1）：255-266
1 randomized clinical trial［J］. JAMA Cardiol，2019，4 ［54］ O’DONOGHUE M L，FAZIO S，GIUGLIANO R P，et al.
（11）：1067-1075 Lipoprotein（a），PCSK9 inhibition，and cardiovascular risk
［46］ BALLANTYNE C M，BANACH M，MANCINI G B J，et ［J］. Circulation，2019，139（12）：1483-1492
al. Efficacy and safety of bempedoic acid added to ezeti⁃ ［55］ ALKHALIL M. Lipoprotein（a）reduction in persons with
mibe in statin ⁃ intolerant patients with hypercholesterol⁃ cardiovascular disease［J］. N Engl J Med，2020，382
emia：a randomized，placebo⁃controlled study［J］. Athero⁃ （21）：65
sclerosis，2018，277：195-203 ［56］SALIBA W，RENNERT H S，BARNETT⁃GRINESS O，et
［47］ RAY K K，BAYS H E，CATAPANO A L，et al. Safety and al. Association of statin use with spontaneous intracere⁃
efficacy of bempedoic acid to reduce LDL cholesterol［J］. bral hemorrhage：a cohort study［J］. Neurology，2018，91
N Engl J Med，2019，380（11）：1022-1032 （5）：400-409
［48］BOWMAN L，HOPEWELL J C，CHEN F，et al. Effects of ［收稿日期］ 2021-06-10